FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137402157> ?p ?o ?g. }

• W2137402157 endingPage "622" @default.
• W2137402157 startingPage "619" @default.
• W2137402157 abstract "See “Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis,” by Moucari R, Asselah T, Cazals–Hatem D, et al on page 416. See “Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis,” by Moucari R, Asselah T, Cazals–Hatem D, et al on page 416. Genes, aging, overweight, and sedentary lifestyle all influence the action of insulin in various organs. Reduction in insulin sensitivity from obesity and a myriad of conditions (Figure 1) results in hyperinsulinemia, which promotes hepatocellular triglyceride accumulation in patients with nonalcoholic fatty liver disease (NAFLD). Basic research, clinical trials and epidemiological studies have provided evidence that the hepatitis C virus (HCV) can independently contribute to insulin resistance as well.1Hui J.M. Sud A. Farrell G.C. et al.Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression.Gastroenterology. 2003; 125: 1695-1704Abstract Full Text Full Text PDF PubMed Scopus (651) Google Scholar, 2Mehta S.H. Brancati F.L. Strathdee S.A. et al.Hepatitis C virus infection and incident type 2 diabetes.Hepatology. 2003; 38: 50-56Crossref PubMed Scopus (337) Google Scholar, 3Shintani Y. Fujie H. Miyoshi H. et al.Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance.Gastroenterology. 2004; 126: 840-848Abstract Full Text Full Text PDF PubMed Scopus (662) Google Scholar, 4Kawaguchi T. Ide T. Taniguchi E. et al.Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2.Am J Gastroenterol. 2007; 102: 570-576Crossref PubMed Scopus (218) Google Scholar, 5Wang C.-S. Wang S.-T. Yao W.-J. et al.Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study.Am J Epidemiol. 2007; 166: 196-203Crossref PubMed Scopus (133) Google Scholar Adding to this growing body of evidence and now providing genotypic association, Moucari et al6Moucari R. Asselah T. Cazals-Hatem D. et al.Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis.Gastroenterology. 2008; 134: 416-423Abstract Full Text Full Text PDF PubMed Scopus (449) Google Scholar implicate infection with viral genotypes 1 or 4 as an independent contributor to insulin resistance. What is “insulin resistance,” and how is it measured? Normally, the rise in insulin in the postprandial state inhibits gluconeogenesis and enhances glucose uptake into muscle and adipose tissue. Rising insulin levels also suppress lipolysis in adipose tissue. Insulin falls during fasting, and this, along with increasing levels of glucagon, epinephrine, and other “counterregulatory hormones,” stimulates glucose production and lipolysis. Obesity is the most common cause of insulin resistance and is characterized by failure of insulin to suppress glucose production, impaired glucose disposal, and postprandial hyperglycemia. As blood glucose levels rise, pancreatic β cells are stimulated to produce more insulin. Hyperinsulinemia in insulin-resistant states coupled with elevated hepatic fatty acid influx leads to fatty liver. Although the hyperinsulinemic–euglycemic clamp is often referred to as the “gold standard” test for assessing insulin resistance, this method is technically challenging and cannot be used in large studies. The Homeostatic Model Assessment (HOMA) offers an estimate of insulin resistance by multiplying the basal (fasting) glucose and insulin concentrations and dividing this product by 22.4 or 403 when the glucose concentration is expressed as millimolar or milligrams per deciliter, respectively. A HOMA score close to 1 indicates normal insulin sensitivity. Insulin resistance is associated with high HOMA scores. Alternatively, taking the log and then the inverse of the insulin and glucose product arrives at the Quantitative Insulin Sensitivity Check Index (QUICKI) score, a numerical transformation considered by some to be more advantageous because the values are more linearly correlated with insulin resistance measurements from the hyperinsulinemic glucose clamp.7Katz A. Nambi S.S. Mather K. et al.Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.J Clin Endocrinol Metab. 2000; 85: 2402-2410Crossref PubMed Scopus (2354) Google Scholar HOMA and QUICKI have the advantage of requiring only a single fasting plasma sample assayed for glucose and insulin, but the primary input data must be accurate and the lack of standardization of insulin assays can be a problem. For the purposes of identifying significant insulin resistance in patients with hepatitis C, Moucari et al6Moucari R. Asselah T. Cazals-Hatem D. et al.Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis.Gastroenterology. 2008; 134: 416-423Abstract Full Text Full Text PDF PubMed Scopus (449) Google Scholar set the threshold high by requiring a HOMA of ≥3. The implication of this relatively stringent threshold is that some of the patients in this study were classified as not being insulin resistant when in fact they likely did have some degree of insulin resistance. Indeed, 4.8% of subjects meeting criteria for metabolic syndrome and 24% of diabetic patients in this study did not have a HOMA >3 at the time of their liver biopsy despite having these clinical sequelae of insulin resistance. The presence of NAFLD might be considered to be perhaps the most sensitive indicator of clinically significant insulin resistance.8Marchesini G. Brizi M. Bianchi G. et al.Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.Diabetes. 2001; 50: 1844-1850Crossref PubMed Scopus (1929) Google Scholar This could explain why in the population that they evaluated with hepatitis C, of whom 50.6% had biopsy evidence of NAFLD, only 32.4% met their HOMA threshold for insulin resistance, and 12.2% had insulin resistance long enough or with sufficient severity that they met the National Cholesterol Education Program criteria for the metabolic syndrome. How HCV infection might cause insulin resistance remains an area of active investigation.9Ratziu V. Heurtier A. Bonyhay L. et al.Review article: an unexpected virus-host interaction—the hepatitis C virus-diabetes link.Aliment Pharmacol Ther. 2005; 22: 56-60Crossref PubMed Scopus (33) Google Scholar, 10Zekry A. McHutchison J.G. Diehl A.M. Insulin resistance and steatosis in hepatitis C virus infection.Gut. 2005; 54: 903-906Crossref PubMed Scopus (54) Google Scholar Studies in cultured cells transfected with viral proteins and transgenic mice expressing HCV proteins have established that these foreign proteins can interfere with both fat trafficking11Lai M.M. Hepatitis C virus proteins: direct link to hepatic oxidative stress, steatosis, carcinogenesis and more.Gastroenterology. 2002; 122: 568-571Abstract Full Text Full Text PDF PubMed Scopus (94) Google Scholar and insulin signaling.3Shintani Y. Fujie H. Miyoshi H. et al.Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance.Gastroenterology. 2004; 126: 840-848Abstract Full Text Full Text PDF PubMed Scopus (662) Google Scholar Cell culture studies of fat trafficking have further identified genotype-specific abnormalities with genotype 3 core protein more likely to cause cellular triglyceride accumulation than other genotype core proteins.12Abid K. Pazienza V. de Gottardi A. et al.An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation.J Hepatol. 2005; 42: 744-751Abstract Full Text Full Text PDF PubMed Scopus (153) Google Scholar This observation correlates with the clinical experience with HCV-infected patients in whom genotype 3 is associated with NAFLD independent of other risk factors, whereas the NAFLD found in patients infected with the other genotypes is associated with the commonly associated risk factors such as obesity and sedentary lifestyle.13Romero-Gómez M. Castellano-Megias V.M. Grande L. et al.Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C.Am J Gastroenterol. 2003; 98: 1135-1141Crossref PubMed Google Scholar, 14Hui J.M. Kench J. Farrell G.C. et al.Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection.J Gastroenterol Hepatol. 2002; 17: 873-881Crossref PubMed Scopus (149) Google Scholar In contrast with the studies of fat trafficking, genotype-specific abnormalities in postreceptor insulin signaling that could help explain the clinical associations found by Moucari et al6Moucari R. Asselah T. Cazals-Hatem D. et al.Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis.Gastroenterology. 2008; 134: 416-423Abstract Full Text Full Text PDF PubMed Scopus (449) Google Scholar have not been described in experimental systems. What comes first in the absence of HCV infection—either NAFLD or insulin resistance—is not entirely clear. Much of the cardiovascular and endocrine literature has attributed insulin resistance to the presence of excessive triglyceride in organs such as the liver and muscle.15den Boer M. Voshol P.J. Kuipers F. et al.Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models.Arterioscler Thromb Vasc Biol. 2004; 24: 644-649Crossref PubMed Scopus (220) Google Scholar, 16Ryysy L. Häkkinen A.M. Goto T. et al.Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients.Diabetes. 2000; 49: 749-758Crossref PubMed Scopus (370) Google Scholar By contrast, accumulating data seem to indicate rather than causing insulin resistance, the presence of visible hepatocyte triglyceride droplets is a consequence of insulin resistance, hyperinsulinemia, and the resulting excessive flux of free fatty acids through the liver.3Shintani Y. Fujie H. Miyoshi H. et al.Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance.Gastroenterology. 2004; 126: 840-848Abstract Full Text Full Text PDF PubMed Scopus (662) Google Scholar, 17Buettner R. Ottinger I. Scholmerich J. et al.Preserved direct hepatic insulin action in rats with diet-induced hepatic steatosis.Am J Physiol Endocrinol Metab. 2004; 286: E828-E833Crossref PubMed Scopus (39) Google Scholar, 18Monetti M. Levin M.C. Watt M.J. et al.Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver.Cell Metab. 2007; 6: 69-78Abstract Full Text Full Text PDF PubMed Scopus (408) Google Scholar In other words, triglyceride droplets may be inert with respect to promoting injury and altered cellular homeostasis and thus simply represent an easily identified morphologic epiphenomenon. In the genotype 3–infected patient, this seems to be the case because fat accumulation does not in itself cause insulin resistance and those patients who are insulin resistant typically have other causes such as obesity.1Hui J.M. Sud A. Farrell G.C. et al.Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression.Gastroenterology. 2003; 125: 1695-1704Abstract Full Text Full Text PDF PubMed Scopus (651) Google Scholar If it is not the viral proteins causing NAFLD, which then cause insulin resistance, then a better understanding is needed to explain how viral proteins might directly impair insulin signaling. A study using transgenic mice expressing the genotype 1b HCV core protein demonstrated that the viral protein impaired insulin signaling, possibly through a mechanism involving circulating tumor necrosis factor (TNF)-α.3Shintani Y. Fujie H. Miyoshi H. et al.Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance.Gastroenterology. 2004; 126: 840-848Abstract Full Text Full Text PDF PubMed Scopus (662) Google Scholar Why TNF-α should cause insulin resistance in this model of liver disease and not in others remains unknown.19Weinman S.A. Belalcazar L.M. Hepatitis C: a metabolic liver disease.Gastroenterology. 2004; 126: 917-919Abstract Full Text Full Text PDF PubMed Scopus (35) Google Scholar Alternatively, HCV core protein expression has been shown to alter postreceptor insulin signaling through its interaction with endogenous P28γ, a protein involved in proteasome activation, HCV core protein degradation and insulin receptor substrate-1 (IRS-1) turnover.20Moriishi K. Okabayashi T. Nakai K. et al.Proteasome activator PA28g-dependent nuclear retention and degradation of hepatitis C virus core protein.J Virol. 2003; 77: 10237-10249Crossref PubMed Scopus (141) Google Scholar The contribution of altered IRS-1 turnover to hepatic insulin resistance is unclear because the role of P28γ in IRS-2 turnover was not described. Using the same genotype 1b core protein transgenic mice, Miyamoto et al21Miyamoto H. Moriishi K. Moriya K. et al.Involvement of the PA28g-dependent pathway in insulin resistance induced by hepatitis C virus core protein.J Virol. 2007; 81: 1727-1735Crossref PubMed Scopus (113) Google Scholar found that knockout of P28γ expression normalized insulin sensitivity by correcting Akt signaling through IRS-2, a major pathway of hepatic postreceptor insulin signaling.21Miyamoto H. Moriishi K. Moriya K. et al.Involvement of the PA28g-dependent pathway in insulin resistance induced by hepatitis C virus core protein.J Virol. 2007; 81: 1727-1735Crossref PubMed Scopus (113) Google Scholar Further evidence supporting this mechanism is that a small molecule proteasome inhibitor was found to block HCV core protein-induced IRS-1 and IRS-2 degradation in transfected hepatoma cells, this occurring in a pathway dependent on suppressor of cytokine signaling (SOCS) 3.22Kawaguchi T. Yoshida T. Harada M. et al.Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3.Am J Pathol. 2004; 165: 1499-1508Abstract Full Text Full Text PDF PubMed Scopus (482) Google Scholar A picture thus emerges of HCV genotype 1b core protein inducing SOCS3, which causes proteasomal degradation of IRS-1/2 and impaired insulin signaling. The findings in these mouse experiments may have been corroborated by a clinical study demonstrating reduced IRS-1 phosphorylation in liver biopsies of HCV patients23Aytug S. Reich D. Sapiro L.E. et al.Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes.Hepatology. 2003; 38: 1384-1392Crossref PubMed Scopus (295) Google Scholar and a more recent study showing increases in IRS-1 and IRS-2 protein levels in liver biopsies and correspondingly improved insulin sensitivity in patients achieving a sustained virologic response to HCV therapy but not in those who failed to respond or relapsed.4Kawaguchi T. Ide T. Taniguchi E. et al.Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2.Am J Gastroenterol. 2007; 102: 570-576Crossref PubMed Scopus (218) Google Scholar Needed now are investigations of the genotypic specificity of these virus–host interactions to determine if genotype-specific interactions lead to differences in SOCS-dependent IRS-1/2 turnover. Studies are also needed to separate out each genotype, and possibly even quasispecies, to further refine the nature of this interaction. Whereas Moucari et al lumped genotypes 1 and 4 to compare with genotypes 2 and 3 in their clinical study, the rationale for doing so is unclear and may be based on the known differences in treatment response between these groups rather than interactions between viral proteins and host signaling pathways. Putting HCV infection on the causal side of insulin resistance has important therapeutic implications. Because the presence of insulin resistance has been associated with a reduction in the response rate of HCV infection to standard therapy,24Harrison S.A. Brunt E.M. Qazi R.A. et al.Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C.Clin Gastroenterol Hepatol. 2005; 3: 604-609Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar one approach has been to investigate whether improving insulin sensitivity before and during treatment of HCV improves the rate of sustained virologic response. If HCV infection is the cause of insulin resistance, and insulin resistance does not directly influence response to treatment, then this will be a failed approach. By contrast, ample experimental evidence exists to support the hypothesis that insulin resistance interferes with mechanisms of viral eradication and thus these remain studies worth pursuing.14Hui J.M. Kench J. Farrell G.C. et al.Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection.J Gastroenterol Hepatol. 2002; 17: 873-881Crossref PubMed Scopus (149) Google Scholar The paper by Moucari et al6Moucari R. Asselah T. Cazals-Hatem D. et al.Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis.Gastroenterology. 2008; 134: 416-423Abstract Full Text Full Text PDF PubMed Scopus (449) Google Scholar adds more texture to the complexity of the interaction between viral proteins and insulin signaling, providing new insight into the roles of genotype and host metabolic responses in progression of liver disease that need further explanation. Like many nuances of the virus–host relationship, understanding these interactions may not influence how we approach patients with our current therapeutic options, but it certainly adds to the foundation upon which future therapies for HCV and metabolic liver disease may be developed. Insulin Resistance in Chronic Hepatitis C: Association With Genotypes 1 and 4, Serum HCV RNA Level, and Liver FibrosisGastroenterologyVol. 134Issue 2PreviewBackground & Aims: Our study was designed to test the association between insulin resistance (IR) and hepatitis C virus (HCV) genotypes, serum HCV RNA level and liver fibrosis stage in a large prospective cohort of chronic hepatitis C (CHC) patients. Methods: Six hundred consecutive patients (CHC, n = 500; chronic hepatitis B (CHB), n = 100) were evaluated on the day of liver biopsy. IR (Homeostasis Model for Assessment of Insulin Resistance) and all components of the metabolic syndrome were assessed. Full-Text PDF" @default.
• W2137402157 created "2016-06-24" @default.
• W2137402157 creator A5073573770 @default.
• W2137402157 date "2008-02-01" @default.
• W2137402157 modified "2023-10-15" @default.
• W2137402157 title "Hepatitis C Virus-Induced Insulin Resistance: Not All Genotypes Are the Same" @default.
• W2137402157 cites W1963876199 @default.
• W2137402157 cites W1967118686 @default.
• W2137402157 cites W1973775519 @default.
• W2137402157 cites W1975004114 @default.
• W2137402157 cites W1980737728 @default.
• W2137402157 cites W1982952696 @default.
• W2137402157 cites W1992357919 @default.
• W2137402157 cites W2018117132 @default.
• W2137402157 cites W2026241394 @default.
• W2137402157 cites W2031170097 @default.
• W2137402157 cites W2036590128 @default.
• W2137402157 cites W2051984446 @default.
• W2137402157 cites W2070183304 @default.
• W2137402157 cites W2082842671 @default.
• W2137402157 cites W2122153547 @default.
• W2137402157 cites W2126327417 @default.
• W2137402157 cites W2130453232 @default.
• W2137402157 cites W2130923541 @default.
• W2137402157 cites W2132477505 @default.
• W2137402157 cites W2151098562 @default.
• W2137402157 cites W2160146665 @default.
• W2137402157 cites W2160518844 @default.
• W2137402157 cites W2615637571 @default.
• W2137402157 cites W4240887102 @default.
• W2137402157 doi "https://doi.org/10.1053/j.gastro.2007.12.041" @default.
• W2137402157 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18242225" @default.
• W2137402157 hasPublicationYear "2008" @default.
• W2137402157 type Work @default.
• W2137402157 sameAs 2137402157 @default.
• W2137402157 citedByCount "6" @default.
• W2137402157 countsByYear W21374021572012 @default.
• W2137402157 countsByYear W21374021572013 @default.
• W2137402157 countsByYear W21374021572015 @default.
• W2137402157 crossrefType "journal-article" @default.
• W2137402157 hasAuthorship W2137402157A5073573770 @default.
• W2137402157 hasBestOaLocation W21374021571 @default.
• W2137402157 hasConcept C104317684 @default.
• W2137402157 hasConcept C126322002 @default.
• W2137402157 hasConcept C135763542 @default.
• W2137402157 hasConcept C159047783 @default.
• W2137402157 hasConcept C2522874641 @default.
• W2137402157 hasConcept C2776408679 @default.
• W2137402157 hasConcept C2777391703 @default.
• W2137402157 hasConcept C2779306644 @default.
• W2137402157 hasConcept C54355233 @default.
• W2137402157 hasConcept C71924100 @default.
• W2137402157 hasConcept C86803240 @default.
• W2137402157 hasConceptScore W2137402157C104317684 @default.
• W2137402157 hasConceptScore W2137402157C126322002 @default.
• W2137402157 hasConceptScore W2137402157C135763542 @default.
• W2137402157 hasConceptScore W2137402157C159047783 @default.
• W2137402157 hasConceptScore W2137402157C2522874641 @default.
• W2137402157 hasConceptScore W2137402157C2776408679 @default.
• W2137402157 hasConceptScore W2137402157C2777391703 @default.
• W2137402157 hasConceptScore W2137402157C2779306644 @default.
• W2137402157 hasConceptScore W2137402157C54355233 @default.
• W2137402157 hasConceptScore W2137402157C71924100 @default.
• W2137402157 hasConceptScore W2137402157C86803240 @default.
• W2137402157 hasIssue "2" @default.
• W2137402157 hasLocation W21374021571 @default.
• W2137402157 hasLocation W21374021572 @default.
• W2137402157 hasOpenAccess W2137402157 @default.
• W2137402157 hasPrimaryLocation W21374021571 @default.
• W2137402157 hasRelatedWork W2016551366 @default.
• W2137402157 hasRelatedWork W2034793309 @default.
• W2137402157 hasRelatedWork W2059010078 @default.
• W2137402157 hasRelatedWork W2068259734 @default.
• W2137402157 hasRelatedWork W2072233926 @default.
• W2137402157 hasRelatedWork W2105597814 @default.
• W2137402157 hasRelatedWork W2121887853 @default.
• W2137402157 hasRelatedWork W2153196018 @default.
• W2137402157 hasRelatedWork W2188759708 @default.
• W2137402157 hasRelatedWork W2400613564 @default.
• W2137402157 hasVolume "134" @default.
• W2137402157 isParatext "false" @default.
• W2137402157 isRetracted "false" @default.
• W2137402157 magId "2137402157" @default.
• W2137402157 workType "article" @default.